Cynata Therapeutics share price jumps 14% on COVID-19 trial

The Cynata Therapeutics Ltd share price leapt 14% this morning as patient enrolment begins on the company's COVID-19 trial.

| More on:
jump in asx share price represented by man leaping up from one wooden pillar to the next

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cynata Therapeutics Ltd (ASX: CYP) share price leapt by as much as 14% this morning as patient enrolment begins on the company's COVID-19 trial.

Cynata is trialling the use of its Cymerus MSC technology in COVID-19 patients with respiratory distress. The study will be conducted in New South Wales with 12 patients to receive Cymerus MSC infusions. Efficacy of the treatment will be assessed according to levels of oxygen in the blood as well as safety and tolerability. 

The Cynata share price has since pulled back slightly to 92 cents per share, up 11.59% on yesterday's close.

What does Cynata Therapeutics do? 

Cynata Therapeutics is a stem cell and regenerative medicine company. It is focused on the development of therapies using its proprietary therapeutic stem cell platform technology, Cymerus. Cymerus is able to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at a commercial scale, without the limitation of multiple donors. 

MSCs are primarily found in the bone marrow and remain dormant until called upon to promote healing within the body. They age as we age, and their number and effectiveness decreases over time. MSCs are at the forefront of a new generation of treatments being investigated for use in treating diseases including osteoarthritis, heart disease, and Crohn's disease. Cynata's Cymerus technology allows cells for therapeutic use to be produced in virtually limitless quantities. 

COVID-19 treatment 

Cynata is now conducting a clinical trial into the use of Cymerus MSCs in the treatment of coronavirus. The trial forms part of a broader clinical development strategy for the Cymerus MSC product to be trialled in COVID-19 patients in other countries.

Commenting on the trial, Cynata's CEO Ross MacDonald said:

Our substantial pre-clinical database in relevant disease models, together with the urgent need for more effective treatments for critically ill patients with COVID-19 patients, allowed us to accelerate planning….we are pleased to be able to move so quickly to further investigate the potential benefits our MSCs could have to treat patients in dire need during this global pandemic.

Cymerus MSCs have demonstrated promising pre-clinical trial results in several conditions that can arise from severe COVID-19 infection, including acute respiratory distress syndrome. Cynata plans to advance Cymerus MSCs into phase 2 trials for severe complications arising from COVID-19 as well as graft versus host disease. A phase 3 trial is planned for osteoarthritis.

The utility of the technology has also been demonstrated in preclinical models of asthma, diabetic wounds, heart attack, sepsis, and acute respiratory distress syndrome. 

Foolish takeaway 

Cynata joins Mesoblast Limited (ASX: MSB) in trialling treatments for COVID-19. The focus on this new clinical development area is a logical step based on the current global environment and Cynata's solid pre-clinical foundations in respiratory and related diseases. 

The Cynata share price is currently trading at 92 cents per share, putting its market cap at just over $100 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 9 January 2025

Motley Fool contributor Kate O'Brien owns shares of CYNATA THR FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Medical or healthcare workers grasp hands in the universal expression of teamwork
Healthcare Shares

Here's how the ASX 200 market sectors stacked up last week

Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

Read more »

Three happy multi-ethnic business colleagues discuss investment or finance possibilities in an office.
Financial Shares

The IAG share price soared 50% in 2024! Here's how

IAG shares smashed the benchmark returns in 2024. But how?

Read more »

A happy boy with his dad dabs like a hero while his father checks his phone.
Opinions

These ASX shares have a legit shot at doubling in 5 years

I’m bullish about the outlook for these stocks for several reasons.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

These ASX 200 shares could rise 20% to 40%

Analysts think these shares could deliver big returns for investors this year.

Read more »

A rueful woman tucks into a sweet pie as she contemplates a decision with regret.
Share Market News

Here are the top 10 ASX 200 shares today

It was a rough end to the week this Friday for ASX shares...

Read more »

Three rockets heading to space
Record Highs

3 ASX 300 shares smashing new multi-year highs while the market struggles

The broader market is in the red on Friday but these three shares are riding high.

Read more »

A fresh-faced young woman holds an Australian flag aloft above her head as she smiles widely on a beach as though celebrating a national day or event where Australia has been successful.
Opinions

The only Australian stocks I own at the start of 2025

My portfolio has a mix of studs and potential duds...

Read more »